{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:51:56Z","timestamp":1793249516337,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006469","name":"Fundo para o Desenvolvimento das Ci\u00eancias e da Tecnologia","doi-asserted-by":"publisher","award":["003\/2018\/A1"],"award-info":[{"award-number":["003\/2018\/A1"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006469","name":"Fundo para o Desenvolvimento das Ci\u00eancias e da Tecnologia","doi-asserted-by":"publisher","award":["0058\/2020\/A2"],"award-info":[{"award-number":["0058\/2020\/A2"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006469","name":"Fundo para o Desenvolvimento das Ci\u00eancias e da Tecnologia","doi-asserted-by":"publisher","award":["0067\/2019\/A2"],"award-info":[{"award-number":["0067\/2019\/A2"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.phrs.2022.106514","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T07:14:56Z","timestamp":1665731696000},"page":"106514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Down-regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer"],"prefix":"10.1016","volume":"186","author":[{"given":"Ying","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen-ling","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Yu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Xing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine Lai-Han","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.phrs.2022.106514_bib1","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2022.106514_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/1874467210801020093","article-title":"Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies","volume":"1","author":"Wu","year":"2008","journal-title":"Curr. Mol. Pharm."},{"key":"10.1016\/j.phrs.2022.106514_bib3","doi-asserted-by":"crossref","first-page":"18789","DOI":"10.1038\/srep18789","article-title":"Nobiletin enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cancer cells","volume":"5","author":"Ma","year":"2015","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.phrs.2022.106514_bib4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2174\/138161282005140214165212","article-title":"ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development","volume":"20","author":"Choi","year":"2014","journal-title":"Curr. Pharmaceut. Des."},{"issue":"5","key":"10.1016\/j.phrs.2022.106514_bib5","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2174\/1871520615666150113103439","article-title":"Development of fourth generation ABC inhibitors from natural products: a novel approach to overcome cancer multidrug resistance","volume":"15","author":"Karthikeyan","year":"2015","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.phrs.2022.106514_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13045-016-0268-z","article-title":"Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer","volume":"9","author":"Wang","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106514_bib7","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","article-title":"Mechanisms of resistance to EGFR tyrosine kinase inhibitors","volume":"5","author":"Huang","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"issue":"Suppl_1","key":"10.1016\/j.phrs.2022.106514_bib8","doi-asserted-by":"crossref","first-page":"Si10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann. Oncol."},{"issue":"Suppl_1","key":"10.1016\/j.phrs.2022.106514_bib9","doi-asserted-by":"crossref","first-page":"Si28","DOI":"10.1093\/annonc\/mdx705","article-title":"Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer","volume":"29","author":"Ricordel","year":"2018","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.phrs.2022.106514_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2016.119","article-title":"ROS homeostasis and metabolism: a critical liaison for cancer therapy","volume":"48","author":"Kim","year":"2016","journal-title":"Exp. Mol. Med."},{"issue":"5","key":"10.1016\/j.phrs.2022.106514_bib11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.it.2009.03.004","article-title":"The protective role of ROS in autoimmune disease","volume":"30","author":"Hultqvist","year":"2009","journal-title":"Trends Immunol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106514_bib12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1089\/ars.2015.6420","article-title":"Targeting tyrosine kinase inhibitor-resistant non-small cell lung cancer by inducing epidermal growth factor receptor degradation via methionine 790 oxidation","volume":"24","author":"Leung","year":"2016","journal-title":"Antioxid. Redox Signal."},{"issue":"45","key":"10.1016\/j.phrs.2022.106514_bib13","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1038\/onc.2011.628","article-title":"Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers","volume":"31","author":"Yamadori","year":"2012","journal-title":"Oncogene"},{"issue":"25","key":"10.1016\/j.phrs.2022.106514_bib14","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1021\/acs.jafc.8b01875","article-title":"Attenuation of terT-butyl Hydroperoxide (t-BHP)-induced oxidative damage in HepG2 cells by tangeretin: relevance of the Nrf2-ARE and MAPK signaling pathways","volume":"66","author":"Liang","year":"2018","journal-title":"J. Agric. Food Chem."},{"issue":"2","key":"10.1016\/j.phrs.2022.106514_bib15","first-page":"179","article-title":"Tangeretin protects renal tubular epithelial cells against experimental cisplatin toxicity","volume":"22","author":"Nazari Soltan Ahmad","year":"2019","journal-title":"Iran. J. Basic Med. Sci."},{"issue":"3\u20134","key":"10.1016\/j.phrs.2022.106514_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000501163","article-title":"Tangeretin inhibits oxidative stress and inflammation via upreguLating Nrf-2 signaling pathway in collagen-induced arthritic rats","volume":"104","author":"Li","year":"2019","journal-title":"Pharmacology"},{"key":"10.1016\/j.phrs.2022.106514_bib17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.phrs.2016.04.003","article-title":"Tangeretin, a citrus pentamethoxyflavone, antagonizes ABCB1-mediated multidrug resistance by inhibiting its transport function","volume":"110","author":"Feng","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106514_bib18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.phrs.2017.09.019","article-title":"Role of tangeretin as a potential bioavailability enhancer for silybin: pharmacokinetic and pharmacological studies","volume":"128","author":"Yuan","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106514_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2019.153141","article-title":"Nobiletin potentiates paclitaxel anticancer efficacy in A549\/T xenograft model: pharmacokinetic and pharmacological study","volume":"67","author":"Feng","year":"2020","journal-title":"Phytomedicine"},{"issue":"25","key":"10.1016\/j.phrs.2022.106514_bib20","doi-asserted-by":"crossref","first-page":"8585","DOI":"10.1523\/JNEUROSCI.2935-13.2014","article-title":"Nrf2 upregulates ATP binding cassette transporter expression and activity at the blood-brain and blood-spinal cord barriers","volume":"34","author":"Wang","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2022.106514_bib21","doi-asserted-by":"crossref","first-page":"7905486","DOI":"10.1155\/2017\/7905486","article-title":"P-glycoprotein (ABCB1) and oxidative stress: focus on Alzheimer's disease","volume":"2017","author":"Sita","year":"2017","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"9","key":"10.1016\/j.phrs.2022.106514_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0256755","article-title":"Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells","volume":"16","author":"Gao","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.phrs.2022.106514_bib23","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s11418-021-01583-1","article-title":"Cardamonin inhibits the expression of P-glycoprotein and enhances the anti-proliferation of paclitaxel on SKOV3-Taxol cells","volume":"76","author":"Ding","year":"2022","journal-title":"J. Nat. Med."},{"issue":"6","key":"10.1016\/j.phrs.2022.106514_bib24","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1021\/mp300668e","article-title":"Dose-dependent targeted suppression of P-glycoprotein expression and function in Caco-2 cells","volume":"10","author":"Lee","year":"2013","journal-title":"Mol. Pharmaceut."},{"issue":"3","key":"10.1016\/j.phrs.2022.106514_bib25","first-page":"1105","article-title":"Liposomal paclitaxel induces fewer hematopoietic and cardiovascular complications than bioequivalent doses of Taxol","volume":"53","author":"Huang","year":"2018","journal-title":"Int. J. Oncol."},{"issue":"12","key":"10.1016\/j.phrs.2022.106514_bib26","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/aps.2016.93","article-title":"Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells","volume":"37","author":"Han","year":"2016","journal-title":"Acta Pharm. Sin."},{"issue":"3","key":"10.1016\/j.phrs.2022.106514_bib27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The different mechanisms of cancer drug resistance: a brief review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Adv. Pharmaceut. Bull."},{"key":"10.1016\/j.phrs.2022.106514_bib28","doi-asserted-by":"crossref","first-page":"5875074","DOI":"10.1155\/2020\/5875074","article-title":"Licochalcone a induces ROS-mediated apoptosis through TrxR1 inactivation in colorectal cancer cells","volume":"2020","author":"Wu","year":"2020","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.phrs.2022.106514_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2018.11.001","article-title":"Modulating ROS to overcome multidrug resistance in cancer","volume":"41","author":"Cui","year":"2018","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.phrs.2022.106514_bib30","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/430939","article-title":"Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy","volume":"2010","author":"Chen","year":"2010","journal-title":"Met.-Based Drugs"},{"issue":"10","key":"10.1016\/j.phrs.2022.106514_bib31","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1161\/01.CIR.0000055318.09997.1F","article-title":"Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes","volume":"107","author":"Suematsu","year":"2003","journal-title":"Circulation"},{"issue":"29","key":"10.1016\/j.phrs.2022.106514_bib32","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1038\/onc.2015.450","article-title":"Oxidative stress enables Epstein-Barr virus-induced B-cell transformation by posttranscriptional regulation of viral and cellular growth-promoting factors","volume":"35","author":"Chen","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.phrs.2022.106514_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12943-017-0657-0","article-title":"PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy","volume":"16","author":"Salaroglio","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phrs.2022.106514_bib34","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.biopha.2018.05.062","article-title":"Nrf2\/P-glycoprotein axis is associated with clinicopathological characteristics in colorectal cancer","volume":"104","author":"Sadeghi","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2022.106514_bib35","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.biopha.2017.10.129","article-title":"Nrf2 overexpression is associated with P-glycoprotein upregulation in gastric cancer","volume":"97","author":"Jeddi","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2022.106514_bib36","doi-asserted-by":"crossref","first-page":"9372182","DOI":"10.1155\/2019\/9372182","article-title":"Activators and inhibitors of NRF2: a review of their potential for clinical development","volume":"2019","author":"Robledinos-Ant\u00f3n","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"11","key":"10.1016\/j.phrs.2022.106514_bib37","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.freeradbiomed.2011.03.008","article-title":"Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2\/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs","volume":"50","author":"Tang","year":"2011","journal-title":"Free Radic. Biol. Med."},{"issue":"10","key":"10.1016\/j.phrs.2022.106514_bib38","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/mc.21921","article-title":"Drug resistance associates with activation of Nrf2 in MCF-7\/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response","volume":"52","author":"Zhong","year":"2013","journal-title":"Mol. Carcinog."},{"issue":"1","key":"10.1016\/j.phrs.2022.106514_bib39","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/15376516.2013.843111","article-title":"Luteolin, a bioflavonoid inhibits Azoxymethane-induced colorectal cancer through activation of Nrf2 signaling","volume":"24","author":"Pandurangan","year":"2014","journal-title":"Toxicol. Mech. Methods"},{"issue":"2","key":"10.1016\/j.phrs.2022.106514_bib40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2443.2010.01473.x","article-title":"Molecular mechanisms of the Keap1\u2013Nrf2 pathway in stress response and cancer evolution","volume":"16","author":"Taguchi","year":"2011","journal-title":"Genes Cells"},{"issue":"11","key":"10.1016\/j.phrs.2022.106514_bib41","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1038\/s41418-019-0303-z","article-title":"DUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer","volume":"26","author":"Zhang","year":"2019","journal-title":"Cell Death Differ."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822004601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822004601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:35:19Z","timestamp":1760913319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822004601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":41,"alternative-id":["S1043661822004601"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106514","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Down-regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106514","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106514"}}